* Core Laboratories Inc CLB.N CLB is expected to show a
rise
in quarterly revenue when it reports results on October 23 for
the period ending September 30 2024
* The Houston Texas-based company is expected to report a
7.3% increase in revenue to $134.455 million from $125.34
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.The company's guidance on July 24
2024, for the period ended September 30, was for revenue between
$131.00 million and $137.00 million.
* LSEG's mean analyst estimate for Core Laboratories Inc is
for
earnings of 23 cents per share. The company's EPS guidance on
July 24 2024, for the period ended September 30, was between
$0.23 and $0.27
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 5
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
Inc is $18.00, below its last closing price of $18.63.
The company's guidance on July 24 2024 for the period ended
September 30 was for Earnings before Interest and Taxes between
USD16.9 million and USD19.1 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.21 0.21 0.22 Beat 6.6
Dec. 31 2024 0.16 0.16 0.19 Beat 21.7
Dec. 31 2023 0.19 0.19 0.19 Met -1.3
Jan. 1 0001 0.22 0.22 0.22 Met -0.1
Jun. 0.20 0.20 0.21 Beat 5.3
30 2023
Mar. 31 2023 0.16 0.16 0.19 Beat 20.3
Dec. 31 2022 0.19 0.20 0.20 Met 2.2
Sep. 30 2022 0.15 0.15 0.18 Beat 20.3
This summary was machine generated October 21 at 22:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)